ArticleProceedings of the National Academy of Sciences of the United States of America2020
Exploiting evolutionary trade-offs for posttreatment management of drug-resistant populations.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 37 citations in OpenAlex.
- Human aminoacyl-tRNA synthetases as integrators of translation and cell signalling networks.Nature reviews. Molecular cell biology · 2026Review
- Covalent Inhibitors in Antimicrobial Drug Development-Beyond β-Lactams.Molecules (Basel, Switzerland) · 2026Review
- Eco-evolutionary dynamics and environmental detoxification jointly shape bacterial community response to antibiotic perturbation.The ISME journal · 2026Article
- Cost of Altered Translation Accuracy Shapes Adaptation to Antibiotics in E. coli.Molecular biology and evolution · 2025Article
- Sequential antibiotic exposure restores antibiotic susceptibility.The Journal of antimicrobial chemotherapy · 2025Article
- Tripartite Loops Reverse Antibiotic Resistance.Molecular biology and evolution · 2025Article
- Private benefit of β-lactamase dictates selection dynamics of combination antibiotic treatment.Nature communications · 2024Article
- Distinguishing mutants that resist drugs via different mechanisms by examining fitness tradeoffs.eLife · 2024Article
- Context-dependent fitness benefits of antibiotic resistance mutations.Proceedings. Biological sciences · 2024Article
- Assessment of bacteriocin production by clinical Pseudomonas aeruginosa isolates and their potential as therapeutic agents.Microbial cell factories · 2024Article
- Distinguishing mutants that resist drugs via different mechanisms by examining fitness tradeoffs.bioRxiv : the preprint server for biology · 2024Article
- Laboratory Evolution of Antimicrobial Resistance in Bacteria to Develop Rational Treatment Strategies.Antibiotics (Basel, Switzerland) · 2024Review
- Article
- Evolution ofGut microbes · 2023Article
- Eco-evolutionary dynamics of experimentalMicrobiology (Reading, England) · 2023Article
- Drug synergy discovery of tavaborole and aminoglycosides against Escherichia coli using high throughput screening.AMB Express · 2022Article
- Spatial structure impacts adaptive therapy by shaping intra-tumoral competition.Communications medicine · 2022Article
- Conditional prediction of consecutive tumor evolution using cancer progression models: What genotype comes next?PLoS computational biology · 2021Article
- Efficacy of epetraborole against Mycobacterium abscessus is increased with norvaline.PLoS pathogens · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
Abstract
Antibiotic resistance frequently evolves through fitness trade-offs in which the genetic alterations that confer resistance to a drug can also cause growth defects in resistant cells. Here, through experimental evolution in a microfluidics-based turbidostat, we demonstrate that antibiotic-resistant cells can be efficiently inhibited by amplifying the fitness costs associated with drug-resistance evolution. Using tavaborole-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.